IMPORTANCE Primary aldosteronism (PA) is an ideal condition to evaluate the role of the mineralocorticoid receptor (MR) in the pathogenesis of atrial fibrillation (AF).
A trial fibrillation is the most common cardiac arrhythmia; it increases the risk for adverse cardiovascular outcomes such as stroke and reduced cardiac output. Prior studies have demonstrated that long-term aldosterone exposure promotes the development of atrial fibrillation by inducing cardiac fibrosis and conduction disturbances via activation of the mineralocorticoid receptor (MR). [1] [2] [3] [4] [5] [6] [7] Recent evidence suggests that blockade of the MR with medications such as spironolactone and eplerenone may provide a new therapeutic approach to prevent or delay the development of atrial fibrillation.
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Primary aldosteronism (PA), a state of autonomous aldosterone secretion, 11 offers a classic example of the detrimental effects of chronic and excessive MR activation on the development of atrial fibrillation. Untreated patients with PA have a 3.5-fold higher risk for incident atrial fibrillation compared with patients with similar blood pressures. 12 Although adrenalectomy as a treatment for PA is associated with decreased risk for atrial fibrillation when compared with patients with essential hypertension, 7 the risk for atrial fibrillation despite lifelong MR antagonist therapy has been reported as high. 7,13 Herein, we conduct a large retrospective cohort study that includes physiologic biomarkers of medical treatment efficacy to examine the risk for incident atrial fibrillation in patients with PA who were treated with MR antagonists or surgical adrenalectomy, compared with patients with essential hypertension.
Methods
We performed a cohort study of patients with PA and patients with essential hypertension using the electronic health records at Brigham and Women's Hospital, Massachusetts General Hospital, and their affiliated partner hospitals (eFigure 1 in the Supplement). 13 Eligibility for the current analyses required that patients had to be seen between 1991 and 2016 and be 18 years or older. Entry into the study was defined by condition: for patients with PA treated with MR antagonists, by the date of the first plasma renin activity (PRA) measurement at least 1 month after starting MR antagonist therapy; for patients with PA treated with surgical adrenalectomy, by the first follow-up visit 1 to 6 months after undergoing surgical adrenalectomy; and for patients with essential hypertension, by the first follow-up visit 1 to 6 months after the diagnosis of essential hypertension was first entered into the medical record. This study was approved by the Partners Healthcare System institutional review board. A waiver of informed consent was granted to develop this deidentified cohort.
Patients with PA who were treated with MR antagonists were subdivided by whether PRA remained suppressed at the first measurement at least 1 month after starting MR antagonist therapy (where suppression was defined as < 1 ng/mL/h) or increased substantially to become unsuppressed (≥ 1 ng/ mL/h). These test results were considered proxies for insufficient and sufficient blockade, respectively, of the MR in PA.
Patients were excluded if they had a history of atrial fibrillation, myocardial infarction or coronary revascularization, transient ischemic attack or stroke, or congestive heart failure hospitalization prior to study entry. Patients with PA who were treated with MR antagonists who and did not have PRA measurements at least 1 month after initiating treatment were also excluded. Patients with essential hypertension were also excluded if they were treated with MR antagonists at study entry. The population with essential hypertension was frequencymatched by decade of age at study entry to the study population with PA who were treated with MR antagonists.
The analysis investigated the risk for incident atrial fibrillation among patients with PA who were treated with MR antagonists or surgical adrenalectomy compared with patients with essential hypertension. We used multivariate Cox regression models (using the PHREG procedure in SAS version 9.4 [SAS Institute]) to estimate adjusted hazard ratios (HRs) and 95% CIs. All models were adjusted for the following covariates at the time of study entry: age, sex, race, body mass index (calculated as weight in kilograms divided by height in meters squared), diabetes mellitus, estimated glomerular filtration rate, and systolic blood pressure. Patients were censored on the date of incident atrial fibrillation or, if they did not develop atrial fibrillation, on the date of their final follow-up visit. All P values are 2-sided and considered significant if .05 or less. A more detailed description of the study cohort, exposure definition, outcome ascertainment, and statistical analysis is available in the eMethods in the Supplement.
Results
A total of 195 patients with PA who were treated with MR antagonists (including 130 whose PRA remained suppressed and 65 whose PRA substantially increased to unsuppressed levels), 201 patients with PA treated with surgical adrenalectomy, and 40 092 patients with essential hypertension were included in the study. Compared with patients with essential hypertension, patients with PA who were treated with MR antagonists were by design of similar age (patients treated with MR antagonists with suppressed PRA: mean [ Patients with PA who were treated with MR antagonists and whose PRA remained suppressed had a higher risk for incident atrial fibrillation compared with patients with essential hypertension (adjusted HR, 2.55 [95% CI, 1.75-3.71]) ( Figure) . In contrast, patients with PA who were treated with MR antagonists and whose PRA rose to become unsuppressed had no statistically significant difference in risk for incident atrial fibrillation compared with patients with essential hypertension (adjusted HR, 1.03 [95% CI, 0.54-2.00]); the same was true for patients with PA who were treated with surgical adrenalectomy (adjusted HR, 0.75 [95% CI, 0.41-1.36]) (Figure; eTable 1 and eTable 2 in the Supplement).
The adjusted 10-year cumulative incidence difference for developing incident atrial fibrillation indicated that patients with PA who were treated with MR antagonists and whose PRA remained suppressed had 14.1 (95% CI, 6.7-21.5) excess cases of atrial fibrillation per 100 persons than patients with essential hypertension ( Table 2) . In contrast, patients with PA who were treated with MR antagonists and whose PRA became unsuppressed, and patients with PA who were treated with surgical adrenalectomy, had no significant difference in the adjusted 10-year cumulative incidence of atrial fibrillation.
Discussion
The findings in this study expand the evidence implicating aldosterone and the MR in the pathogenesis of atrial fibrillation. Without targeted treatment, PA is associated with a 3.5-fold higher risk for developing atrial fibrillation than essential hypertension, independent of blood pressure. 12 We previously showed that even when MR antagonists are used in PA, the risk for atrial fibrillation in these patients is 1.9-fold higher than in patients with essential hypertension. 13 However, the current analyses demonstrate that this risk may be modified by the way medical treatment is implemented: when PA is treated with MR antagonists such that renin remains suppressed, the risk for developing atrial fibrillation is 2.5-fold higher than in age-matched patients with essential hypertension and similar blood pressures. In contrast, treating PA with MR antagonists to induce a substantial increase in renin or with surgery to remove the source of autonomous aldosterone secretion results in no significant difference in the risk for developing atrial fibrillation. Renin suppression in PA is a result of excessive MR activation and sodium and volume expansion, 11,14 and the increase in renin with MR antagonist therapy reflects sufficient antagonism of the MR and decreased sodium reabsorption and volume contraction. Indeed, an increase in renin with MR antagonists in PA has previously been shown to be associated with a lower risk for myocardial infarction, stroke, heart failure, and death.
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The current study provides clinically relevant evidence from an extreme state of hyperaldosteronism that using MR antagonists to adequately block the MR, or removal of the unilateral source of aldosterone excess via surgical adrenalectomy, may mitigate the excess risk for atrial fibrillation attributed to pathologic MR activation. These findings are in agreement with recent studies in essential hypertension and heart failure, 8-10,15 which suggest that blockade of the MR may be a potential target for preventing or delaying the incidence of atrial fibrillation and stroke. Our findings may also help contextualize prior studies in cohorts with PA that did not include an evaluation of physiological biomarkers of MR blockade and observed that lifelong MR antagonist therapy did not lower the risk for atrial fibrillation, whereas surgical adrenalectomy did.
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Limitations
Our results must be interpreted within the limitations of this observational study design. Despite blood pressure and other risk factors being similar at study entry and our models adjusting for important confounders, there may still be residual confounding and misclassification. Although the population of patients with PA was relatively large compared with prior cohort studies in PA, the absolute sample sizes of the study populations were still small and could therefore limit the reliability of our conclusions. Although we performed extensive medical record reviews to confirm the atrial fibrillation outcomes, the reliance on medical record documentation for this ascertainment cannot completely exclude some misclassification. Because this study used an open cohort design, we could not capture all atrial fibrillation events that occurred outside of our health care system, which may have resulted in an underestimation of cumulative incidence rates. Patients with PA who were treated with surgery were on average 7 years younger than the other exposure groups, a reflection of the fact that unilateral PA is often more severe and presents earlier in life. However, our models were adjusted for age, and the comparisons using the surgical exposure can be considered to strengthen the differences observed among patients treated with MR antagonists, who were matched by age to patients with essential hypertension. Finally, we defined renin suppression using a binary categorization, rather than using a continuous analysis of renin values, because most patients with PA had renin activity values that were below the lower limit of the assay (0.60 ng/mL/h).
Conclusions
In conclusion, the excess risk for atrial fibrillation that is attributed to aldosterone-MR interactions in PA may be miti- . e Refers to the first blood pressure recorded after first plasma renin activity measurement at least 1 month after starting MRA therapy, 1 to 6 months after undergoing surgical adrenalectomy, or 1 to 6 months after initial ICD-9 or ICD-10 coding for essential hypertension. f The mean MRA equivalent potency is a metric to allow consolidation of spironolactone and eplerenone doses into a single potency. Spironolactone is considered to be twice the potency of eplerenone for this calculation; therefore, dosing was calculated by multiplying total daily dose of spironolactone by 2 and eplerenone by 1.
g The other antihypertensive medication category includes hydralazine, clonidine, α-blockers, nitrates, minoxidil, methyldopa, and direct renin inhibitors.
gated by MR antagonist therapy that sufficiently blocks aldosterone or by surgical adrenalectomy to remove the source of aldosterone excess. These findings provide additional support for the role of aldosterone and the MR in the pathogen- 
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PA treated with MRA therapy; plasma renin activity <1 ng/mL/h PA treated with MRA therapy; plasma renin activity ≥1 ng/mL/h Essential hypertension PA treated with adrenalectomy Solid lines indicate adjusted cumulative incidence; dashed lines indicate unadjusted cumulative incidence. Hazard ratios (HRs) were adjusted for and cumulative incidence curve standardized to the distribution of age, sex, race, body mass index, diabetes mellitus, estimated glomerular filtration rate, and systolic blood pressure at the time of study entry in the cohort. The adjusted HR was 2.55 (95% CI, 1.75-3.71) for patients with primary aldosteronism whose primary renin activity level was <1 ng/mL/h compared with patients with essential hypertension; 1.03 (95% CI, 0.54-2.00) for patients with primary aldosteronism whose primary renin activity was 1 ng/mL/h or more compared with patients with essential hypertension; 0.75 (95% CI, 0.41-1.36), for patients with primary aldosteronism treated with surgery compared with patients with essential hypertension. MRA indicates mineralocorticoid receptor antagonist; PA, primary aldosteronism. 
Statistical Analysis:
The analysis investigated the risk for incident atrial fibrillation among PA patients treated with MR antagonists or surgical adrenalectomy compared with patients with essential hypertension.
We used multivariate Cox regression models (proc PHREG in SAS v9.4, Cary, NC) to estimate adjusted hazard ratios and 95% confidence intervals. All models were adjusted for the following covariates at the time of study entry: age, sex, race, body mass index, diabetes mellitus, estimated glomerular filtration rate, and systolic blood pressure. The proportional hazards assumption was evaluated by testing significance of the exposure-time interactions in the Cox models. Stratified modeling (proc PHREG strata statement in SAS v9.4) was used to account for any variables that violated the proportional hazards assumption and showed no appreciable change in the results. The standardized cumulative incidence of atrial fibrillation was one minus a standardized survival function (proc PHREG baseline statement in SAS v9.4), which was estimated by averaging the estimated individual-specific survival curves based on the multivariate Cox models mentioned above over the distributions of the aforementioned covariates in the cohort. We used this model to calculate differences in standardized cumulative incidence of atrial fibrillation at 2, 5, and 10 years of follow-up. Patients were censored on the date of incident atrial fibrillation or, if they did not develop atrial fibrillation, on the date of their final follow-up visit. All p-values are two-sided. The analyses were repeated using the second and third plasma renin activity measurements (for those PA patients who had multiple measurements after initiating MR antagonist therapy) (Supplemental Table 1 ).
Additionally, we attempted to analyze renin as a continuous measure, without transformation and with log transformation (Supplemental Table 2 ). However, this analysis was limited as the vast majority (109/130 or 84%) of patients with a physiologically suppressed
